WO1999065537A1 - Implantation superficielle et revetement superficiel pour extenseurs et autres implants - Google Patents
Implantation superficielle et revetement superficiel pour extenseurs et autres implants Download PDFInfo
- Publication number
- WO1999065537A1 WO1999065537A1 PCT/EP1999/003919 EP9903919W WO9965537A1 WO 1999065537 A1 WO1999065537 A1 WO 1999065537A1 EP 9903919 W EP9903919 W EP 9903919W WO 9965537 A1 WO9965537 A1 WO 9965537A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tantalum
- stents
- surface coating
- base material
- implants
- Prior art date
Links
- 238000000576 coating method Methods 0.000 title claims abstract description 22
- 239000011248 coating agent Substances 0.000 title claims abstract description 17
- 239000007943 implant Substances 0.000 title claims abstract description 16
- 229910052715 tantalum Inorganic materials 0.000 claims abstract description 34
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 31
- 229910052758 niobium Inorganic materials 0.000 claims abstract description 11
- 239000010955 niobium Substances 0.000 claims abstract description 11
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910001220 stainless steel Inorganic materials 0.000 claims description 12
- 239000010935 stainless steel Substances 0.000 claims description 12
- 238000002513 implantation Methods 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910000831 Steel Inorganic materials 0.000 claims description 3
- 239000010959 steel Substances 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 229910001092 metal group alloy Inorganic materials 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 abstract description 6
- 230000037237 body shape Effects 0.000 abstract 1
- 238000005260 corrosion Methods 0.000 description 11
- 230000007797 corrosion Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
- 229910052737 gold Inorganic materials 0.000 description 10
- 239000010931 gold Substances 0.000 description 10
- 239000011148 porous material Substances 0.000 description 8
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000031481 Pathologic Constriction Diseases 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 239000010970 precious metal Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NRTOMJZYCJJWKI-UHFFFAOYSA-N Titanium nitride Chemical compound [Ti]#N NRTOMJZYCJJWKI-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910000859 α-Fe Inorganic materials 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 230000002965 anti-thrombogenic effect Effects 0.000 description 1
- 229910001566 austenite Inorganic materials 0.000 description 1
- 229910000963 austenitic stainless steel Inorganic materials 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005468 ion implantation Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000817 safety factor Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/088—Other specific inorganic materials not covered by A61L31/084 or A61L31/086
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Definitions
- the invention relates to a surface implantation or surface coating for stents and other implants according to the preamble of claim 1
- stents implants for healing bones (screws, plates, etc.), dental implants, cardio- and cardio-surgical implants (e.g. thoracic wires, defibrillators and pacemakers and their electrodes, coronary stents, etc.), endoprostheses, vena Cava filter, etc. used.
- cardio- and cardio-surgical implants e.g. thoracic wires, defibrillators and pacemakers and their electrodes, coronary stents, etc.
- endoprostheses e.g. thoracic wires, defibrillators and pacemakers and their electrodes, coronary stents, etc.
- endoprostheses e.g. thoracic wires, defibrillators and pacemakers and their electrodes, coronary stents, etc.
- endoprostheses e.g. thoracic wires, defibrillators and pacemakers and their electrodes, coronary stents,
- niobium and tantalum are the two elements that have been implanted in a living body and have produced no or the least defense reactions .
- (coronary) stents have been made from materials such as (full) tantalum, stainless steel, nitinol, etc. Since after a stent has been implanted in a previously narrowed coronary vessel, it will try to narrow again within 6 months with a probability of up to 45%, which is known as re-stenosis various manufacturers of such stents, by surface coating with gold, carbon, radioactive isotopes, etc., to achieve better results.
- Gold and platinum are generally considered to be biocompatible.
- stainless steel stents are electroplated with an approximately 5 ⁇ m thick gold layer.
- Modern PVD processes are an alternative to galvanic processes. In order to achieve good adhesion to the stent surface, these must first be chemically cleaned and pickled in order to be able to remove greases, dirt residues and, last but not least, the chromium oxide layer, which protects against corrosion.
- gold is noble compared to the stainless steel base material and builds up an electrical potential difference to it.
- Titanium nitride is also considered to be biocompatible.
- the coating is carried out using the PVD process. Titanium nitride is very hard (> 2500HV) and has a comparatively high elastic modulus. Similar to gold, similar problems occur or are exacerbated, because the low ductility of the layer compared to gold means that the layers tend to crack even more when the stent is expanded; In this respect, an increased risk of pitting in the base material must be taken into account.
- stents require good elasticity with very good support strength.
- the mechanical parameters that characterize this are expressed in the elongation at break of the material and in its modulus of elasticity.
- austenitic stainless steel 316 L with subgroups etc. (DIN 1.4435) has a maximum elongation at break of almost 80% and a modulus of elasticity of 210 GPa. The most favorable conditions. Other materials such as titanium or tantalum are much less favorable in this regard.
- titanium similar to tantalum, a maximum elongation at break of 30% can be set, but on average only between 10-15% Overexpansions (eg expansion through the balloon catheter) quickly lead to crack formation.
- the modulus of elasticity for titanium is 110-120 GPa and for tantalum 160-170 GPa. Mechanically, the classic material "stainless steel” therefore has clear advantages for this application compared to the "new materials”.
- Stainless steel stents lead to the strong formation of neointimal hyperplasia, are thrombogenic and have a thermodynamic residual risk of ion release into the surrounding biological environment.
- Stents e.g. austenitic steel 316 L or the like have a comparatively high corrosion sensitivity.
- the causes are, on the one hand, the relatively inhomogeneous structure and, on the other hand, the residues of "delta" ferrite in the austenite. None of the stents customary in the market was completely “delta” ferrite.
- Coatings should remedy this.
- a 5 ⁇ m thick gold surface is offered as a coating on the market. Gold builds up a very high pitting sensitivity to the base material, so that increased corrosion occurs especially over pores and on the rough cut surfaces. This is even stronger than with uncoated stents.
- the present invention is based on the object of combining favorable mechanical properties of the base material with the biocompatible properties of tantalum or niobium.
- the layers should be electrochemically compatible with the base material and must not build up any pitting potential. This happens primarily with noble and electrically conductive layers such as gold or platinum. Due to the expansion of the stent, cracking and pore formation in the layer can never be completely avoided. This can lead to increased corrosion and thus ion release of the base material via the "pitting" potential.
- the layers must have exceptionally good adhesion to stainless steel.
- the smallest layer flaking in vivo carries the risk of embolism.
- the production of the layers should therefore include thermal and thermodynamic redundant safety factors. These are achieved using the PVD (Physical Vapor Depositation) process. This also minimizes the internal stresses of the layer and the base material.
- tantalum is considered the most body-friendly metal among materials.
- results and findings that are available on the use of tantalum.
- tantalum is the most chemically resistant metal, in some respects it is even more stable than the precious metals.
- tantalum has the advantage over precious metals that it tends to spontaneously self-passivate while building up an electrically insulating layer. As a result, the formation of pitting potentials can be completely ruled out.
- the reactions of the metal tantalum (Ta) to its oxide or hydroxy oxide can partially or completely increase pores and cracks, depending on the size; this process is known as soap sealing. Corrosion tests confirm the exceptional protection that tantalum layers on stainless steel stents can offer.
- Bipolar surfaces are formed by chemical bonding with nitrogen and oxygen to form tantalum oxynitrides, which leads to preferential adsorption of albumin from the blood. This creates the prerequisites for setting a surface that is both biocompatible and improved in terms of thrombogenicity.
- tantalum also shows moderate x-ray contrast on stents, i.e. the stent is easily visible on the screen or image, but you can still look into the stent. This makes it easier to diagnose even stenoses in the stent than e.g. is the case with pure stainless steel stents.
- a tantalum / tantalum ceramic layer composite is applied in several layers to the base material in layer thicknesses of up to 5 micrometers or more, so that largely continuous pores to the substrate can be avoided. But even if continuous pores occur, one can speak of chemically and electrochemically dense layers: firstly due to the above-discussed soap sealing effects of the layer and secondly due to the formation of electrically insulating passive layers. The corrosion results confirm this impressively.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Selon l'invention, il est prévu de réaliser une implantation superficielle ou un revêtement superficiel avec un matériau différent du matériau de base, pour des extenseurs ou d'autres implants qui restent de façon permanente ou provisoire dans le corps d'un homme ou d'un animal et qui comportent un corps de base, en un matériau de base, qui est formé en fonction d'exigences mécaniques ou géométriques. Etant donné que la surface ou que le revêtement superficiel est constituée de tantale ou de niobium, les propriétés mécaniques favorables du matériau de base peuvent se combiner avec les propriétés biocompatibles du tantale ou du niobium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU46061/99A AU4606199A (en) | 1998-06-12 | 1999-06-08 | Superficial implant and surface coating for stents and other implants |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE29810483U DE29810483U1 (de) | 1998-06-12 | 1998-06-12 | Oberflächenimplantation oder Oberflächenbeschichtung für Stents oder andere Implantate |
| DE29810483.0 | 1998-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999065537A1 true WO1999065537A1 (fr) | 1999-12-23 |
Family
ID=8058410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1999/003919 WO1999065537A1 (fr) | 1998-06-12 | 1999-06-08 | Implantation superficielle et revetement superficiel pour extenseurs et autres implants |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU4606199A (fr) |
| DE (1) | DE29810483U1 (fr) |
| WO (1) | WO1999065537A1 (fr) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002005863A1 (fr) * | 2000-07-14 | 2002-01-24 | Advanced Cardiovascular Systems, Inc. | Stent radio-opaque en alliage binaire |
| WO2002043787A1 (fr) * | 2000-11-28 | 2002-06-06 | Fortimedix B.V. | Stent |
| WO2002068007A1 (fr) | 2001-02-26 | 2002-09-06 | Danfoss A/S | Implant et procede de modification de la surface d'un implant |
| WO2005065737A1 (fr) * | 2003-12-24 | 2005-07-21 | Biotronik Vi Patent Ag | Marqueur radio-opaque pour implants medicaux |
| WO2011141169A1 (fr) | 2010-05-11 | 2011-11-17 | Medacta International S.A. | Substrat pour articulations orthopédiques résistantes à l'usure, en un métal non ferreux avec un revêtement à base de nitrure |
| DE10145714B4 (de) * | 2000-09-18 | 2012-07-26 | Inflow Dynamics, Inc. | Stent |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402173B2 (en) | 2000-09-18 | 2008-07-22 | Boston Scientific Scimed, Inc. | Metal stent with surface layer of noble metal oxide and method of fabrication |
| US7101391B2 (en) | 2000-09-18 | 2006-09-05 | Inflow Dynamics Inc. | Primarily niobium stent |
| DE10357334A1 (de) * | 2003-12-05 | 2005-07-07 | Grönemeyer, Dietrich H. W., Prof. Dr.med. | MR-kompatibles medizinisches Implantat |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400408A (en) * | 1980-05-14 | 1983-08-23 | Permelec Electrode Ltd. | Method for forming an anticorrosive coating on a metal substrate |
| US4969907A (en) * | 1985-01-08 | 1990-11-13 | Sulzer Brothers Limited | Metal bone implant |
| US5477864A (en) * | 1989-12-21 | 1995-12-26 | Smith & Nephew Richards, Inc. | Cardiovascular guidewire of enhanced biocompatibility |
| US5573839A (en) * | 1991-04-30 | 1996-11-12 | Saint-Gobain Vitrage International | Glass substrate coated with thin multifilms for protection against solar radiation |
| EP0824900A2 (fr) * | 1996-08-22 | 1998-02-25 | Advanced Cardiovascular Systems, Inc. | Revêtement protecteur pour un Stent muni d'une couche radio-opaque intermédiaire |
| FR2765095A1 (fr) * | 1997-06-27 | 1998-12-31 | Alain Guinounet | Dispositif medical implantable destine a etre visse dans l'os des machoires, afin de recevoir une prothese dentaire provisoire |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2152594C (fr) | 1993-01-19 | 1998-12-01 | David W. Mayer | Extenseur en materiau composite cladde |
| US5630840A (en) | 1993-01-19 | 1997-05-20 | Schneider (Usa) Inc | Clad composite stent |
| NO311781B1 (no) | 1997-11-13 | 2002-01-28 | Medinol Ltd | Flerlags-stenter av metall |
-
1998
- 1998-06-12 DE DE29810483U patent/DE29810483U1/de not_active Expired - Lifetime
-
1999
- 1999-06-08 AU AU46061/99A patent/AU4606199A/en not_active Abandoned
- 1999-06-08 WO PCT/EP1999/003919 patent/WO1999065537A1/fr active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4400408A (en) * | 1980-05-14 | 1983-08-23 | Permelec Electrode Ltd. | Method for forming an anticorrosive coating on a metal substrate |
| US4969907A (en) * | 1985-01-08 | 1990-11-13 | Sulzer Brothers Limited | Metal bone implant |
| US5477864A (en) * | 1989-12-21 | 1995-12-26 | Smith & Nephew Richards, Inc. | Cardiovascular guidewire of enhanced biocompatibility |
| US5562730A (en) * | 1989-12-21 | 1996-10-08 | Smith & Nephew Richards, Inc. | Total artificial heart device of enhanced hemocompatibility |
| US5573839A (en) * | 1991-04-30 | 1996-11-12 | Saint-Gobain Vitrage International | Glass substrate coated with thin multifilms for protection against solar radiation |
| EP0824900A2 (fr) * | 1996-08-22 | 1998-02-25 | Advanced Cardiovascular Systems, Inc. | Revêtement protecteur pour un Stent muni d'une couche radio-opaque intermédiaire |
| FR2765095A1 (fr) * | 1997-06-27 | 1998-12-31 | Alain Guinounet | Dispositif medical implantable destine a etre visse dans l'os des machoires, afin de recevoir une prothese dentaire provisoire |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002005863A1 (fr) * | 2000-07-14 | 2002-01-24 | Advanced Cardiovascular Systems, Inc. | Stent radio-opaque en alliage binaire |
| DE10145714B4 (de) * | 2000-09-18 | 2012-07-26 | Inflow Dynamics, Inc. | Stent |
| WO2002043787A1 (fr) * | 2000-11-28 | 2002-06-06 | Fortimedix B.V. | Stent |
| WO2002068007A1 (fr) | 2001-02-26 | 2002-09-06 | Danfoss A/S | Implant et procede de modification de la surface d'un implant |
| US7156851B2 (en) | 2001-02-26 | 2007-01-02 | Danfoss A/S | Implant and process of modifying an implant surface |
| WO2005065737A1 (fr) * | 2003-12-24 | 2005-07-21 | Biotronik Vi Patent Ag | Marqueur radio-opaque pour implants medicaux |
| US8871829B2 (en) | 2003-12-24 | 2014-10-28 | Biotronik Vi Patent Ag | Radio-opaque marker for medical implants |
| WO2011141169A1 (fr) | 2010-05-11 | 2011-11-17 | Medacta International S.A. | Substrat pour articulations orthopédiques résistantes à l'usure, en un métal non ferreux avec un revêtement à base de nitrure |
Also Published As
| Publication number | Publication date |
|---|---|
| DE29810483U1 (de) | 1999-10-14 |
| AU4606199A (en) | 2000-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60309281T3 (de) | Verbesserte Metalllegierung für medizinische Geräte und Implantate | |
| EP2457601B1 (fr) | Composite de marqueur et implant médical doté d'un marqueur de radiographie | |
| EP1696978B1 (fr) | Marqueur radio-opaque pour implants medicaux | |
| DE10145714B4 (de) | Stent | |
| US6287332B1 (en) | Implantable, bioresorbable vessel wall support, in particular coronary stent | |
| EP2014317B1 (fr) | Implant doté d'une couche de diffusion contenant du magnésium proche de la surface et son procédé de fabrication | |
| EP0923389B1 (fr) | Implant metallique degradable in vivo | |
| EP2172580B1 (fr) | Implant et methode de fabrication dudit implant | |
| EP0388576B1 (fr) | Implant métallique | |
| EP0447744B1 (fr) | Procédé pour fabriquer des surfaces ostéointégrantes d'implants du squelette aussi bien qu'un implant du squelette | |
| DE19856983A1 (de) | Implantierbare, bioresorbierbare Gefäßwandstütze, insbesondere Koronarstent | |
| DE102008043970A1 (de) | Verfahren zur Herstellung einer korrosionshemmenden Beschichtung auf einem Implantat aus einer biokorrodierbaren Magnesiumlegierung sowie nach dem Verfahren hergestelltes Implantat | |
| WO1999065537A1 (fr) | Implantation superficielle et revetement superficiel pour extenseurs et autres implants | |
| DE102006038242A1 (de) | Stent mit einer Struktur aus einem biokorrodierbaren metallischen Werkstoff | |
| EP2415489B1 (fr) | Implant revêtu d'agents polylactiques issu d'un alliage de magnésium biocorrodable | |
| EP2206526A2 (fr) | Pâte implantable et son utilisation | |
| EP3068452A1 (fr) | Implant à charge superficielle négative élevée | |
| EP2332588A2 (fr) | Implant biocorrodable doté d'un revêtement anticorrosion | |
| DE102012210804B4 (de) | Verfahren zur Erzeugung einer bakteriziden Schicht auf einem Grundkörper aus Titan oder einer Titanbasislegierung | |
| EP1618918A1 (fr) | Electrode implantable | |
| DE10107675B4 (de) | Endoprothese und Verfahren zu ihrer Herstellung | |
| EP2433660B1 (fr) | Implant revêtu en alliage de magnésium biocorrodable | |
| EP4072606B1 (fr) | Implant, composant d'implant et méthode pour leur production | |
| WO1998052489A1 (fr) | Membrane barriere biocompatible | |
| DE102018113810A1 (de) | Funktionsmarkerelement und Verfahren zu dessen Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BA BB BG BR CA CN CU CZ DE EE GD GE GH GM HR HU ID IL IN IS JP KE KP KR LC LK LR LS LT LV MG MK MN MX NO NZ PL RO RU SD SG SI SK SL TR TT UA UG US UZ VN YU ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |